With recent data demonstrating intracranial efficacy of small molecule tyrosine-kinase inhibitors (particularly tucatinib) in ERBB2-positive MBC,28,32 the survival of patients with ERBB2-positive breast cancer BRM is likely to improve even further over time. This evidence concerns the gene ERBB2 and breast carcinoma.